Document:

EX-10.18

 Exhibit 10.18 

 

			
	

	 	

 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would
be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

GRANT AGREEMENT 
 [***] 

AGREEMENT SUMMARY & SIGNATURE PAGE 
  

			
	GRANTEE INFORMATION
		
	Name:	  	LumiraDx UK Limited
	Tax Status:	  	 Not exempt from federal income tax under U.S. IRC § 501(c)(3)

You confirm that the above information is correct and agree to notify the Foundation immediately of any change.

	Expenditure Responsibility:	  	 This Agreement is subject to “expenditure responsibility” requirements under the

U.S. Internal Revenue Code.

	Mailing Address:	  	3 More London Riverside, London, SE1 2AQ, GBR
	Primary Contact:	  	Nigel Lindner, Chief Innovation Officer, [***]
	
	FOUNDATION INFORMATION
		
	Mailing Address:	  	[***]
	Primary Contact:	  	Shirley Chen, Deputy Director, Strategy, Planning and Management, Innovation, [***]
	
	AGREEMENT INFORMATION
		
	Title:	  	COVID-19: LumiraDx LMIC manufacturing capacity expansion
	“Charitable Purpose”:	  	to expand test strip manufacturing capacity for access to volume for LMICs
	“Start Date”:	  	Date of last signature
	“End Date”:	  	December 31, 2022
	This Agreement includes and incorporates by this reference:	  	 This Agreement Summary & Signature Page and:
  

•  Grant Amount and Reporting & Payment Schedule (Attachment A)

 
 •  Terms and Conditions
(Attachment B)
  
 •  Additional
Global Access Commitments (Attachment C)
  

•  Investment Document (date submitted October 16, 2020)

 
 •  Budget (date submitted
October 8, 2020)

 THIS AGREEMENT is between LumiraDx UK Limited (“You” or “Grantee”) the Bill &
Melinda Gates Foundation (“Foundation”), and Gates Philanthropy Partners (“GPP”), and is effective as of the date of last signature. Each party to this Agreement may be referred to individually as a
“Party” and together as the “Parties.” GPP and the Foundation may be referred to collectively as the “Funders.” As a condition of this grant, the Parties enter into this Agreement by having their
authorized representatives sign below. 
  

									
	BILL & MELINDA GATES FOUNDATION	 		 	LUMIRADX UK LIMITED
					
	By:	 	 /s/ Shirley Chen
	 		 	By:	 	 /s/ Veronique Ameye

	Name:	 	 Shirley Chen
	 		 	Name:	 	 Veronique Ameye

	Date:	 	 November 6, 2020
	 		 	Date:	 	 November 7, 2020

				
	GATES PHILANTHROPY PARTNERS	 		 		 	
					
	By:	 	 /s/ Robert Rosen
	 		 		 	
	Name:	 	 Robert Rosen
	 		 		 	
	Date:	 	 November 6, 2020
	 		 		 	

  
 1 of 9 

 GRANT AGREEMENT 

[***] 
 ATTACHMENT A

 GRANT AMOUNT AND REPORTING & PAYMENT SCHEDULE 

GRANT AMOUNT 
 The Funders will pay You the total grant
amount specified in the Reporting & Payment Schedule below. The Foundation’s Primary Contact must approve in writing any Budget cost category change of more than [***]. 

REPORTING & PAYMENT SCHEDULE 
 Payments are
subject to Your compliance with this Agreement, including Your achievement, and the Foundation’s approval, of any applicable targets, milestones, and reporting deliverables required under this Agreement. The Foundation may, in its reasonable
discretion, modify payment dates or amounts and will notify You of any such changes in writing. 
 REPORTING 

You will submit reports according to the Reporting & Payment Schedule using the Foundation’s templates or forms, which the Foundation will make
available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress
has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify the Foundation’s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve
any such changes in writing. You agree to submit other reports the Foundation may reasonably request. 
 ACCOUNTING FOR PERSONNEL TIME 

You will track the time of all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds.
Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and brief descriptions of tasks performed. You will report actual time worked consistent with those records in Your
progress and final budget reports. You will submit copies of such records to the Foundation upon request. 
  

											
		 	REPORTING & PAYMENT SCHEDULE
	 Investment

Period        
	 	 Target,
Milestone,
or Reporting
Deliverable
	 	 Due By
	 	 Payment Date
	 	 Foundation

Payment
 Amount
(U.S.$)
	 	 GPP Payment
Amount (U.S.$)

		 	[***]	 		 	[***]	 		 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	
		 	[***]	 	[***]	 		 		 	
	[***]	 	[***]	 	[***]	 		 		 	
	[***]	 	[***]	 	[***]	 		 		 	
	 Subtotals for each Funder
	 		 		 	[***]	 	[***]
	 Total Grant Amount
	 		 		 		 	[***]

  
 2 of 9 

 GRANT AGREEMENT 

[***] 
 ATTACHMENT B

 TERMS & CONDITIONS 
 This
Agreement is subject to the following terms and conditions. 
 PROJECT SUPPORT 

PROJECT DESCRIPTION AND CHARITABLE PURPOSE 
 The awarding
You this grant to carry out the project described in the Investment Document (“Project”) in order to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Investment Document. 
 MANAGEMENT OF FUNDS 

USE OF FUNDS 
 You may not use funds provided under this
Agreement (“Grant Funds”) for any purpose other than the Project. You may not use Grant Funds to reimburse any expenses You incurred prior to the Start Date. At the Foundation’s request, You will repay any portion of Grant
Funds and/or Income used or committed in material breach of this Agreement, as determined by the Foundation in its discretion. 
 INVESTMENT OF FUNDS

 You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank accounts
or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or losses) and
the amount of any interest or other income generated by the Grant Funds (collectively, “Income”). Any Income must be used for the Project. 

SEGREGATION OF FUNDS 
 You must maintain Grant Funds in a
physically separate bank account or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project. 
 GLOBAL
ACCESS 
 GLOBAL ACCESS COMMITMENT 
 You will conduct
and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will survive the term of this Agreement. “Funded Developments” means the products, services, processes,
technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). “Background Technology”
means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. “Global
Access” means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people
most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project. 

GLOBAL ACCESS COMMITMENT AGREEMENT 
 In order to further
define Your Global Access commitments, You agree to the terms and conditions set forth in the Additional Global Access Commitments Agreement set forth in Attachment C. You may not materially change the plans or strategies contained in any Global
Access Commitment Agreement without the Foundation’s prior written approval. Upon request of the Foundation, You will provide the Foundation with progress updates evidencing the progress to attain Your Global Access Commitments. 

  
 3 of 9 

 PUBLICATION 

Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You
will seek prompt Publication of any Funded Developments consisting of data and results. “Publication” means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or
otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers
Global Access. If You seek Publication in a peer-reviewed journal, such Publication shall be under “open access” terms and conditions consistent with the Foundation’s Open Access Policy available at:
www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time. Nothing in this section shall be construed as
requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (e.g., © 20<> <Name>). 
 INTELLECTUAL PROPERTY REPORTING 

During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports relating to the Funded Developments,
Background Technology, and any related agreements using the Foundation’s templates or forms, which the Foundation may modify from time to time. 

SUBGRANTS AND SUBCONTRACTS 
 SUBGRANTS AND SUBCONTRACTS

 You may not make subgrants under this Agreement. You have the exclusive right to select subcontractors to assist with the Project. 

RESPONSIBILITY FOR OTHERS 
 You are responsible for
(a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of
this Agreement. 
 PROHIBITED ACTIVITIES 

ANTI-TERRORISM 
 You will not use funds provided under this
Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or
controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the
expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion. 

ANTI-CORRUPTION; ANTI-BRIBERY 
 You will not offer or
provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Funders or the Project, including by assisting any party to secure an improper advantage.
Training and information on compliance with these requirements are available at www.learnfoundationlaw.org. 
 POLITICAL ACTIVITY AND ADVOCACY

 You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use
Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local,
state, federal, or foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project. 

  
 4 of 9 

 OTHER 

PUBLICITY 
 A Party may publicly disclose information about
the award of this grant, including the other Party’s name, the total amount awarded, and a description of the Project, provided that a Party obtains prior written approval before using the other Party’s name for promotional purposes or
logo for any purpose. Any public disclosure by You or Your subgrantees, subcontractors, contingent workers, agents, or affiliates must be made in accordance with the Foundation’s then-current brand guidelines, which are available at:
www.gatesfoundation.org/brandguidelines. 
 LEGAL ENTITY AND AUTHORITY 

You confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in
which You are organized or formed; (b) You are not an individual (i.e., a natural person) or a disregarded entity (e.g., a sole proprietor or sole-owner entity) under U.S. law; (c) You have the right to enter into and fully perform this
Agreement; and (d) Your performance will not violate any agreement or obligation between You and any third party. You will notify the Foundation immediately if any of this changes during the term of this Agreement. 

COMPLIANCE WITH LAWS 
 In carrying out the Project, You
will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual property, privacy, or publicity rights of any third party. 

COMPLIANCE WITH REQUIREMENTS 
 You will conduct, control,
manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards (“Requirements”). You will
obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity. As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance
with all Requirements. 
 If the Project involves: 
 a. any
protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Funders without obtaining the Foundation’s prior written approval and all necessary consents
to disclose such information; 
 b. children or vulnerable subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or

 c. any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the International Council on Harmonization (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 
 Any activities by
the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all Requirements for the Project. 

RELIANCE 
 You acknowledge that the Funders are relying on
the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Funders may continue to rely on this information and on any additional
information You provide regarding activities, progress, and Funded Developments. 
 INDEMNIFICATION 

If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms,
experimental medicine, or the provision of medical/health services (“Indemnified Activities”), You will indemnify, defend, and hold harmless the Funders and their respective trustees, directors, officers, employees, and agents, as
applicable (“Indemnified Parties”) from and against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments,
settlements, or costs or expenses (including reasonable attorneys’ fees and expenses) (collectively, “Claims”) arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees,
subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by the Funders in connection with the Project, such as its review or proposal of suggested modifications to the
Project, will not modify or waive the Foundation’s rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are
limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this
Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if any. 

  
 5 of 9 

 INSURANCE 

You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted
industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section. 

TERM AND TERMINATION 
 TERM 

This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The Foundation, in its
discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements. 

TERMINATION 
 The Funders may modify, suspend, or
discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes to Your leadership or other factors that the
Foundation reasonably believes may threaten the Project’s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this Agreement. 

RETURN OF FUNDS 
 Any Grant Funds, plus any Income, that
have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly to the Foundation. 

MONITORING, REVIEW, AND AUDIT 
 The Foundation may monitor
and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may include onsite visits to assess Your organization’s governance, management and operations, discuss Your program and finances, and
review relevant financial and other records and materials. In addition, the Foundation may conduct audits, including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully spent. Any
onsite visit or audit shall be conducted at the Foundation’s expense, following prior written notice, during normal business hours, and no more than once during any 12-month period. 

INTERNAL OR THIRD PARTY AUDIT 
 If during the term of this
Agreement You are audited by your internal audit department or by a third party, You will provide the audit report to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed
(“Remediation Plan”). The Remediation Plan must include (a) details of actions You will take to correct any deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies.

 RECORD KEEPING 
 You will maintain complete and
accurate accounting records and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation’s request, You will make
such records and reports available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed. 
 SURVIVAL 

A Party’s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this
Agreement or otherwise required by law or intended by their nature. 

  
 6 of 9 

 GENERAL 

ENTIRE AGREEMENT, CONFLICTS, AND AMENDMENTS 
 This
Agreement contains the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. If there is a conflict between this Agreement and the Investment Document this Agreement will prevail.
Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties. 

NOTICES AND APPROVALS 
 Written notices, requests, and
approvals under this Agreement must be delivered by mail or email to the Foundations or Your primary contact, as applicable, specified on the Agreement Summary & Signature Page, or as otherwise directed by the other applicable Party. The
Foundation will be responsible for sharing any notices or requests You provide to the Foundation and obtaining any consents from GPP as needed. 

SEVERABILITY 
 Each provision of this Agreement must be
interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect. 

ASSIGNMENT 
 You may not assign, or transfer by operation
of law or court order, any of Your rights or obligations under this Agreement without the Foundation’s prior written approval. This Agreement will bind and benefit any permitted successors and assigns. 

COUNTERPARTS AND ELECTRONIC SIGNATURES 
 Except as may be
prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute
one agreement. Facsimile and electronic signatures will be binding for all purposes. 

  
 7 of 9 

 GRANT AGREEMENT 

[***] 
 ATTACHMENT C

 ADDITIONAL GLOBAL ACCESS COMMITMENTS 

In furtherance of the Charitable Purpose as outlined in the Proposal and set forth in the Amended and Restated Letter Agreement dated as of October 17,
2019, Company agrees to the following additional Global Access Commitments. Capitalized terms not defined herein shall have the same meaning as in the Grant Agreement. In consideration of the Foundation making the grant on the terms and conditions
in the Grant Agreement and herein, and for other good and valuable consideration, You hereby irrevocably agree as follows: 
  

	 	1.	 Commercially reasonable efforts to sell. For a period from the Effective Date until December 31, 2030, in
each calendar year, the You will (a) participate in all Procurement Opportunities from Purchasers applicable to the Products; (b) use reasonable commercial efforts to secure purchase orders pursuant to such Procurement Opportunities; and
(c) use reasonable commercial efforts to accept and fulfill all such purchase orders for Product so secured from Purchasers in at least the Reserved Quantities, in each case only for distribution in Eligible Countries. 

 

	 	2.	 Maximum Prices: Sales of Products to Purchasers for use in Eligible Countries will be made at a price per unit
no greater than the Maximum Prices. All sales to Purchasers shall be made Ex Works, at the Your facility (Incoterms 20210) unless otherwise agreed by You and the applicable Purchaser. 

 

	 	3.	 With this manufacturing capacity expansion investment, the Foundation will have priority access to the maximum
volume available via one delta line beginning in 2022 through [***], i.e. up to maximum of 150,000,000 test strips per year; [***]. The upfront payment of [***] in [***] shall secure [***] in 2021 (i.e. [***], up to a maximum of 50 million
strips). 

  

	 	4.	 Defined Terms: 

“Eligible Countries” means the countries set forth on Exhibit X 

“Maximum Prices” means for each Product, a price not to exceed the applicable price set forth on Exhibit X. 

“Purchasers” means any entity or organization that is purchasing Product for use in the Eligible Countries, including government
agencies, procurement organizations, and other agreed and designated organizations. 
 “Procurement Opportunities” means all bona
fide opportunities to sell Products to Purchasers within the Reserved Quantities as defined below 
 “Reserved Quantities” means,
on an annual basis, the quantities of the Grantee’s products listed on Exhibit X. Such quantities are deemed reserved Eligible Country access based on quarterly forecasts provided by Grantee and mutually agreed between you and the Foundation no
later than the 15th day of the last month of the preceding quarter. Any quantities not reserved by this date shall not be required to be reserved for Eligible Country access and may be reallocated for sale to Your other commercial markets. 

The Grantee shall provide regular updates on opportunities and allocation and will consult with the Foundation to maximize opportunities and
decide on priorities (as it will not be possible to tackle all countries at the same time). The Foundation will, where feasible, introduce or provide linkages to procurement 

  
 8 of 9 

 organizations and government agencies to accelerate access where feasible. It is understood
that the implementation requires the cooperation and acceptance of Purchasers and their acceptance to purchase instruments and roll out testing. 

Exhibit X 

Eligible Countries are defined in Exhibit Y: The Parties will negotiate in good faith additional jurisdictions which may be added by mutual
executed amendment to this grant agreement. Products are defined as: [***] instruments, or the molecular, low-cost/ruggedized equivalent versions (collectively, the “Instruments”). All test strips on
the LumiraDx Instruments developed and commercialized from the Effective Date through December 31, 2030 (collectively, the “Test Strips”). Maximum prices are defined as: 

 

	 	•	 	 Instruments: [***] 

  

	 	•	 	 Test Strips: 

  

	 	•	 	 For SARS-COV-2 Ag tests, [***].

  

	 	•	 	 For SARS-CoV-2 Ab tests, [***].

  

	 	•	 	 LumiraDx shall discuss with the Foundation in good faith, no later than [***], additional adjustments that can be
made to the pricing for SARS-CoV-2 antibody or antigen tests from [***]. 

  

	 	•	 	 Other tests: From [***], pricing in no event shall exceed [***] per strip for the base strip. If more complex
strips are launched, which have additional costs or additional components (example molecular), pricing will be discussed and agreed in good faith taking into consideration these Global Access requirements. HIV pricing shall be as per Bill &
Melinda Gates Foundation agreements, per [***]. 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Pricing references base test strip only and does not include accessories such as swabs, vials, printers, carry
cases, barcodes etc which will be provided at commercially reasonable pricing where available and needed and agreed in good faith taking into consideration these Global Access requirements 

Reserved Quantities of Test Strip manufacturing capacity of a maximum of 50,000,000 for 2021, [***]. 

Reserved Quantities of Test Strip manufacturing capacity of a maximum of 150,000,000 for 2022 through [***]. 

Reserved Quantities of LumiraDx Instruments for 2021 and 2022; up to [***]. 

  
 9 of 9Exhibit 4.2

 

RLX TECHNOLOGY INC.

 

	
Number
    	
 
    	
Class A   Ordinary Shares
    

 

Incorporated under the laws of the Cayman Islands

 

Share capital is US$150,000 divided into 15,000,000,000 shares comprising of 
 (i) 12,000,000,000 Class A Ordinary Shares of a par value of US$0.00001 each 
 (ii) 1,500,000,000 Class B Ordinary Shares of a par value of US$0.00001 each and 
 (iii) 1,500,000,000 shares of a par value of US$0.00001 each of such class or classes (however designated) 
 as the board of directors may determine in accordance with Article 9 of the Articles

 

 

THIS IS TO CERTIFY THAT                                                                        is the registered holder of                                                    Class A Ordinary Shares in the above-named Company subject to the Memorandum and Articles of Association thereof.

 

 

EXECUTED on behalf of the said Company on the                          day of                                               by:

 

 

 

	
DIRECTOR

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]